HLB Pharmaceutical (Korea) Investor Sentiment

047920 Stock  KRW 22,250  250.00  1.11%   
About 62% of HLB Pharmaceutical's investor base is looking to short. The analysis of current outlook of investing in HLB Pharmaceutical Co suggests that many traders are alarmed regarding HLB Pharmaceutical's prospects. The current market sentiment, together with HLB Pharmaceutical's historical and current headlines, can help investors time the market. In addition, many technical investors use HLB Pharmaceutical stock news signals to limit their universe of possible portfolio assets.
  
over a week ago at news.google.com         
HLB Therapeutics Co.,Ltd.s Shares Climb 36 percent But Its Business Is Yet to Catch Up - Simply Wall...
Google News at Macroaxis
over a month ago at news.google.com         
HLB acquires controlling stake in top domestic enzyme producer -
Google News at Macroaxis
over six months ago at news.google.com         
HLB Therapeutics Co.,Ltd.s Popularity With Investors Under Threat As Stock Sinks 26 percent - Simply...
Google News at Macroaxis
over six months ago at news.google.com         
Can HLB receive US FDA approval for Rivoceranib liver cancer drug after initial failure -
Google News at Macroaxis
over six months ago at news.google.com         
The lower price of HLB, a bio-company triggered on the 17th, is expected to cause a considerable aft...
Google News at Macroaxis
over six months ago at news.google.com         
The KOSDAQ also fell nearly 2 percent due to the impact of HLB group stocks, which all hit the lower...
Google News at Macroaxis
over six months ago at news.google.com         
HLB hit by US FDAs rejection of Rivoceranib liver cancer drug - koreatimes
Google News at Macroaxis
over six months ago at news.google.com         
Korea-U.S. Semiconductors continued to rise for three consecutive trading days, with ultra-high scor...
Google News at Macroaxis
over six months ago at news.google.com         
The EcoPro transaction, which is considered a representative secondary holding company in Korea, res...
Google News at Macroaxis
over six months ago at news.google.com         
HLB Therapeutics Co.,Ltd.s 38 percent Share Price Surge Not Quite Adding Up - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Pharmaceutical and bio-related stocks, which have been showing record stock price growth this year, ...
Google News at Macroaxis
over six months ago at news.google.com         
Subdued Growth No Barrier To HLB bioStep Co.,Ltd. With Shares Advancing 29 percent - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Stock supervisors net bought bio stocks such as Hanmi Pharmaceutical, HLB Biostep, Samchondang Pharm...
Google News at Macroaxis
over six months ago at news.google.com         
As of 930 a.m. on the 27th, the top 1 percent of stock investment returns were net buyers of Alteoge...
Google News at Macroaxis
over six months ago at news.google.com         
The top 1 percent of stock investment returns were net buyers of Samsung Electronics, HLB, and Samhy...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about HLB Pharmaceutical that are available to investors today. That information is available publicly through HLB media outlets and privately through word of mouth or via HLB internal channels. However, regardless of the origin, that massive amount of HLB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of HLB Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of HLB Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to HLB Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive HLB Pharmaceutical alpha.

HLB Pharmaceutical Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for HLB Stock analysis

When running HLB Pharmaceutical's price analysis, check to measure HLB Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLB Pharmaceutical is operating at the current time. Most of HLB Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of HLB Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLB Pharmaceutical's price. Additionally, you may evaluate how the addition of HLB Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Fundamental Analysis
View fundamental data based on most recent published financial statements
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories